Thalidomide is an immunomodulatory and anti-inflammatory drug that was initially developed as a sedative in the 1950s. However, it was later found to have teratogenic effects and was withdrawn from the market. In the 1990s, thalidomide was rediscovered for its potential therapeutic effects in treating various inflammatory and autoimmune conditions. In dermatology, thalidomide has been used to treat a variety of skin diseases, including erythema nodosum leprosum, lupus erythematosus, pyoderma gangrenosum, and graft-versus-host disease. It has also been used as an off-label treatment for prurigo nodularis, cutaneous sarcoidosis, and other refractory dermatoses.

The exact mechanism of action of thalidomide is not fully understood, but it is known to modulate the immune system and reduce inflammation through multiple pathways. It is thought to inhibit the production of various cytokines and chemokines involved in inflammation and promote apoptosis of activated T-cells. Thalidomide also has anti-angiogenic properties, which may contribute to its therapeutic effects in skin diseases.

Although thalidomide has shown promising results in the treatment of various skin diseases, it is not without its risks. Thalidomide is known to cause birth defects and is contraindicated in pregnancy. Other potential adverse effects of thalidomide include drowsiness, peripheral neuropathy, and thromboembolic events. Regular monitoring is required for patients receiving thalidomide therapy, and its use should be carefully considered in each individual case.

In this learning module, you will learn about the different dermatological conditions that can be treated with thalidomide, its mechanism of action, indications, contraindications, adverse effects, and drug interactions.

To test your knowledge, we invite you to complete the associated quiz.

Select how you would like to proceed below:

1. Bolognia, J., Cerroni, L., & Schaffer, J. V. (2018). Dermatology. Philadelphia: Elsevier.

2. Wolverton, S. E. (2021). Comprehensive dermatologic drug therapy. Edinburgh: Saunders.